ERBB2 and neoplasm: Since factors such as HER2 overexpression, PD-L1 positivity, or MSI-H may elevate tumor heterogeneity [21, 29, 30], independent grouping based on any single biomarker could increase heterogeneity within control cohorts, thereby compromising the model’s discriminative capacity.